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Study objective: To study the effect of long-term smoking on all-cause and cause-specific mortality, and to
estimate the effects of cigarette and cigar or pipe smoking on life expectancy.
Design: A long-term prospective cohort study.
Setting: Zutphen, The Netherlands.
Participants: 1373 men from the Zutphen Study, born between 1900 and 1920 and studied between 1960
and 2000.
Measurements: Hazard ratios for the type of smoking, amount and duration of cigarette smoking, obtained
from a time-dependent Cox regression model. Absolute health effects of smoking are expressed as differences
in life expectancy and the number of disease-free years of life.
Main results: Duration of cigarette smoking was strongly associated with mortality from cardiovascular
disease, lung cancer and chronic obstructive pulmonary disease, whereas both the number of cigarettes
smoked as well as duration of cigarette smoking were strongly associated with all-cause mortality. Average
cigarette smoking reduced the total life expectancy by 6.8 years, whereas heavy cigarette smoking reduced
the total life expectancy by 8.8 years. The number of total life-years lost due to cigar or pipe smoking was
4.7 years. Moreover, cigarette smoking reduced the number of disease-free life-years by 5.8 years, and
cigar or pipe smoking by 5.2 years. Stopping cigarette smoking at age 40 increased the life expectancy by
4.6 years, while the number of disease-free life-years was increased by 3.0 years.
Conclusions: Cigar or pipe smoking reduces life expectancy to a lesser extent than cigarette smoking. Both the
number of cigarettes smoked and duration of smoking are strongly associated with mortality risk and the
number of life-years lost. Stopping smoking after age 40 has major health benefits.
S
moking has been recognised as a health hazard for many
years. Smoking causes a wide range of diseases, including
cancer, chronic obstructive pulmonary disease (COPD) and
cardiovascular diseases (CVD), and smoking cessation has
impressive health benefits.1–3 Cigarette smoking cessation
decreases the risk of diseases and also increases life expectancy.
Even stopping at age 60 gains about 3 years of life expectancy.4
Much less is known about the adverse effects of long-term cigar
or pipe smoking.5–7
Smoking has both long- and short-term effects. As smoking
habits change during life, information on long-term smoking
history is required to obtain correct estimates of the long-term
health effects of smoking. Because in most studies the level of
detail on smoking history is limited, the impact of various
aspects of the smoking history remains unclear. Leffondre´ et al8
show the importance of information on smoking duration,
intensity and time since cessation in this respect. Although
smoking duration has been associated with mortality before,
most studies focused on cancer mortality rather than on CVD
and COPD mortality.9–15
In epidemiological studies, hazard ratios are commonly used
to express the impact on mortality. Hazard ratios express effects
for one exposure group relative to the effect of the unexposed
group—that is, the reference group—but do not give informa-
tion regarding absolute public health effects. Therefore, life
expectancies should be calculated. Although concepts like life
expectancy are more informative and readily grasped by all,
they are not reported frequently.
The objective of this study is to assess the relationships
between long-term cigarette, cigar or pipe smoking, and
duration and the number of cigarettes smoked, and mortality.
To obtain accurate effect estimates, we used repeated measures
of smoking habits collected in a 40-year period and adjusted for
potential confounders. In addition to hazard ratios, we present
our results also in terms of changes in life expectancy at age 40
and the number of disease-free years of life due to cigarette and
cigar or pipe smoking.
MATERIALS AND METHODS
Study population
The Zutphen Study was started as the Dutch contribution to the
Seven Countries Study, a longitudinal study of the relationships
between diet, other risk factors and chronic diseases.16 The
Zutphen Study has been carried out since 1960 among middle-
aged men in Zutphen, an old industrial town in the eastern part
of the Netherlands with about 25 000 inhabitants. In 1960, a
random sample was drawn of 1088 men born between 1900
and 1919 and residing for at least 5 years in Zutphen. Of these,
878 (81%) men participated in the Zutphen Study and 872 men
took part in both dietary and medical examinations. The
examinations were repeated in 1965, 1970, 1985, 1990, 1995
and 2000. In 1985, the group of 554 survivors was extended
with a new random sample of men of the same age. Of the 1266
men who were invited, 939 (74%) men participated and 825
(65%) men took part in both dietary and medical examinations.
These examinations were repeated in 1990, 1995 and 2000.
Baseline data were collected in 1960 before the Helsinki
Declaration was developed, and oral informed consent was
obtained in view of follow-up data. In 1985 and 1990, the study
was approved by the Medical Ethics Committee of the
Abbreviations: BMI, body mass index; COPD, chronic obstructive
pulmonary disease; CVD, cardiovascular disease; DM, diabetes mellitus;
MI, myocardial infarction
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University of Leiden, The Netherlands, and in 1995 and 2000,
by the Medical Ethics Committee of the Netherlands
Organisation for Applied Scientific Research (TNO).
Assessment of smoking habits
Information on smoking habits was collected using standar-
dised questionnaires. From 1960 until 1990, detailed informa-
tion was gathered on type and amount of smoking (cigarette,
cigar and pipe). The 1995 and 2000 questionnaires combined
cigar and pipe smoking, and participants were asked whether
they still smoked and how much they smoked per day. In 1960
and 1985, information on the age at smoking initiation and, in
case of former smokers, age at cessation was collected for
cigarette smoking. Duration of cigarette smoking was calcu-
lated using information on duration of smoking at baseline and
information on smoking in the following measurement years.
In addition, we calculated time until death or censoring since
smoking cessation. As the number of men who smoked a pipe
was small, men who smoked a cigar, pipe or both were
considered as one group. Additionally, we created an overall
smoking variable, combining cigarette and cigar or pipe
smoking. This study has a relatively small sample size and
the number of never smokers is very small. Consequently, for
cigarette, cigar or pipe and overall smoking, men were divided
into categories of never or long-term ex-smokers—that is,
stopped smoking >10 years ago, recent ex-smokers—that is,
stopped smoking ,10 years ago, and current smokers. At the
start of this study, the number of current smokers was very
high and decreased remarkably during 40 years of follow-up.
As similar trends in smoking habits were seen in the general
Dutch population, the information on smoking habits was
considered valid.
Assessment of potential confounders
Information on food consumption was collected using the
cross-check dietary history method, adapted to the Dutch
situation.17 18 Energy and alcohol intake was calculated using
food composition tables close to the year of measurement. The
participants were divided into two groups according to alcohol
use (yes or no). Alcohol use was defined as having at least 1 g
of alcohol intake per day, which is equivalent to about one
alcoholic beverage per week.
During medical examinations, the weight and height of men
were measured and body mass index (BMI) was calculated (kg/
m2). Information about the prevalence and history of myocar-
dial infarction (MI), stroke, diabetes mellitus (DM) and cancer
was collected throughout the study. Men were classified into
four levels of socioeconomic status (manual workers, non-
manual workers, small business owners and professionals)
according to occupation at baseline.
Case assessment
Participants were followed until death, or censoring on 30 June
2000. During the study, six participants were lost to follow-up
and were censored after their last physical examination. The
final causes of death were ascertained by one clinical
epidemiologist, and coded according to the International
Classification of Diseases, Eighth Revision (codes 410.0–414.9
for coronary heart disease, codes 390.0–459.9 for CVD, codes
140.0–208.9 for cancer, codes 162.0–162.9 for lung cancer and
codes 490.0–492.9 and 496 for COPD). As the underlying cause
of death in elderly people is often difficult to ascertain, we
included primary, secondary and tertiary causes of death in our
analyses.
Statistical analysis
Cox proportional hazard analyses were performed with age as
the time variable, with smoking information updated at each
measurement round. In addition, we modelled the effects of
duration of cigarette smoking (per 10 years), the number of
cigarettes smoked (per 10 cigarettes per day) and time since
cigarette smoking cessation (per 5 years), both separately as
well as combined.8 As many smokers quit at the time of serious
illness, the number of cigarettes smoked was adjusted for ever
smoking (yes or no). The duration of smoking and the time
Table 1 Characteristics of men participating in the Zutphen Study by year of measurement
1960 1965 1970 1985 1990 1995 2000
Number of participants
1960 cohort 872 721 615 349 231 114 51
1985 cohort — — — 476 306 161 68
Cumulative number of deaths
1960 cohort — 48 109 429 561 670 766
1985 cohort — — — — 97 232 364
Age (years) 49 (6) 54 (5) 59 (5) 71 (5) 75 (5) 80 (4) 83 (3)
Overall smoking (%)
Never and long-term ex-smoker* 6 6 9 26 50 60 72
Recent ex-smoker 6 11 15 31 17 16 14
Cigarettes and cigars or pipes 52 35 25 7 4 2 0
Cigarettes 23 26 29 23 19 16 6
Cigars or pipes 14 21 23 13 10 6 8
Duration of cigarette smoking
(years)`
1960 cohort 29 (11) 34 (14) 34 (14) 39 (18) 40 (19) 42 (20) 37 (21)
1985 cohort — — — 33 (21) 32 (22) 29 (22) 28 (20)
Energy without alcohol (kcal) 3082 (673) 2921 (673) 2539 (539) 2147 (507) 2029 (459) 2033 (469) 1992 (457)
Alcohol (percentage users) 36 59 69 70 66 68 75
BMI (kg/m2) 24.1 (2.7) 24.9 (2.7) 25.2 (2.8) 25.5 (3.1) 25.5 (3.2) 25.3 (3.4) 26.0 (3.3)
Values are represented as mean (SD), unless indicated otherwise.
*Never and long-term ex-smokers are defined as men who never smoked or stopped smoking >10 years ago.
Recent ex-smokers are defined as men who stopped smoking ,10 years ago.
`Mean duration of cigarette smoking includes the men who never smoked (duration = 0).
108 Streppel, Boshuizen, Ocke´ , et al
www.tobaccocontrol.com
since cigarette smoking cessation were adjusted for age at
initiation.
We determined differences in life expectancies at age 40 and
the number of disease-free years of life between current
smokers and never or long-term ex-smokers, by calculating
the area under survival curves. For disease-free years of life,
survival until the age of onset of MI, stroke, DM or cancer was
used. Smokers who stopped smoking during follow-up were
excluded from the analyses from the moment they stopped, and
men who started smoking during follow-up were included in
the analyses from the moment they started. The differences in
life expectancy and the number of disease-free years of life due
to cigar or pipe smoking were studied among men who were
never or long-term ex-cigarette smokers. In addition, we
calculated differences in life expectancy and the number of
disease-free years of life for different ages at cigarette smoking
cessation (age 40, 50, 60 or 70 years) compared with continuing
smoking at that age and for every 10 cigarettes per day increase.
A Cox proportional hazard model, with age as the time variable,
was used to obtain the survival curves, adjusted for baseline
covariates. For those men who started the study in 1960, values
in 1960 were used as baseline values, whereas, for those who
started the study in 1985, values in 1985 were used as baseline
values. 95% CIs were obtained using the bootstrap method.19
For Cox proportional hazard models, the PHREG procedure
of SAS/STAT software V.9.1 was used. The covariates in
multivariate models included energy intake (kcal/day), use of
alcohol (yes/no), BMI (kg/m2) and baseline socioeconomic
status (manual workers, non-manual workers, small business
owners and professionals), and were updated at each measure-
ment round. We adjusted for the prevalence of MI (yes/no),
stroke (yes/no), DM (yes/no) and cancer (yes/no), updating this
information at each measurement round, to account for the
possibility that smokers quit smoking because of serious illness.
Furthermore, cigarette smoking was adjusted for cigar or pipe
smoking. All available data were used for the analysis.
RESULTS
Table 1 shows the major characteristics of the men participating
in the Zutphen Study during 40 years of follow-up (mean
follow-up of all participants: 28 years). During follow-up, 1130
of the 1373 men died: CVD was the primary cause of death in
36% of all deaths, and coronary heart disease in 20% of all
deaths. Total cancer, lung cancer and COPD were the primary
cause in respectively, 26%, 10% and 4% of all deaths,
respectively. Of the men who were included in the study in
1960, 74% smoked cigarettes in 1960. Among those men who
were still alive in 2000, 12% were current cigarette smokers
(fig 1A). The percentage of current smokers was lower among
the men who were newly included in 1985. Moreover, the
current smokers in 1960 had an average cigarette smoking
duration of 17 years during 40 years of follow-up. For the
current smokers in 1985, this figure was 7 years. Among
smokers, the number of cigarettes smoked per day decreased
from 13 to 3 cigarettes in the period 1960–2000. In 1960, the
percentage of cigar or pipe smokers among those men who
were never or long-term ex-cigarette smokers was 54% (fig 1B).
These exclusive cigar or pipe smokers smoked, on average, three
cigars and six pipes per day. Again, the percentage of exclusive
cigar or pipe smokers was lower among men who were newly
included in 1985. The percentage of alcohol users doubled from
36% in 1960 to 75% in the period 1985–2000. Average energy
intake, without alcohol, decreased substantially from
3082 kcal/day to 1992 kcal/day. Average BMI increased from
24.1 kg/m2 in 1960 to 26.0 kg/m2 in 2000.
Using updated information at each measurement round and
after adjustment for potential confounders, smoking was
strongly associated with all-cause and cause-specific mortality
(table 2). Hazard ratios (HRs) for current cigarette smoking
varied between 1.40 (95% CI 1.07 to 1.83) for cancer mortality
and 2.90 (1.80 to 4.68) for COPD mortality. The associations
between recent ex-smoking and mortality were weaker, and
varied between 1.15 (0.84 to 1.57) and 2.98 (1.78 to 5.01) for
cancer and COPD mortality, respectively. In general, the
associations between smoking and mortality were stronger for
overall smoking compared with cigarette smoking.
Furthermore, for cardiovascular mortality we found a signifi-
cant and inverse interaction between smoking status and
survival age. This indicates that the association between
smoking status and cardiovascular mortality weakens with a
higher survival age.
Every 10-year increase in cigarette smoking duration was
strongly associated with mortality from all causes (HR at mean
survival age 1.12), CVD (HR 1.15), lung cancer (HR at mean
survival age 1.31) and COPD (HR 1.38), independent of the
number of cigarettes smoked (table 3). In addition, every 10
cigarettes per day increase was associated with all-cause
mortality (HR 1.11), independent of smoking duration
(table 3). When studying the association between duration of
cigarette smoking and lung cancer mortality, we found a
significant and inverse interaction with survival age. This
indicates that the association between duration of cigarette
smoking and mortality weakens with a higher survival age.
Moreover, omitting the adjustment for the prevalence of
chronic diseases attenuated our results slightly, but the overall
conclusions remained the same, except for cancer mortality. For
total cancer mortality, the HR for every 10 cigarettes per day
increase increased from 1.14 (0.97 to 1.32) to 1.24 (1.06 to 1.43)
and the HR for every 10-year increase in cigarette smoking
duration increased from 1.07 (0.96 to 1.19) to 1.11 (1.01 to
Figure 1 Changes in cigarette (A) and exclusive cigar or pipe (B) smoking
within the Zutphen Study, during 40 years of follow-up. Changes in
exclusive cigar or pipe smoking were studied among those men who were
never or long-term ex-cigarette smokers. *Recent ex-smokers are defined
as men who stopped smoking ,10 years ago; never and long-term ex-
smokers are defined as men who never smoked or stopped smoking
>10 years ago.
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1.22), whereas for lung cancer mortality these HRs changed
from 1.14 (0.90 to 1.44) to 1.32 (1.11 to 1.58) and from 1.31
(1.07 to 1.60) to 1.25 (1.06 to 1.47), respectively. As duration of
smoking and the time since cessation were strongly and
inversely correlated (r(20.78), we were not able to include
both in the same model. The separate associations of time since
cigarette smoking cessation with mortality were opposite to the
association for smoking duration (data not shown). Age at
initiation of cigarette smoking did not independently contribute
to mortality risk and was therefore left out of the models.
Figure 2 shows the adjusted survival curve used for
determining life expectancies at age 40. Current cigarette
smoking reduced life expectancy by 6.8 years and the number
of disease-free years of life—that is, years free from MI, stroke,
Table 2 Smoking in relation to mortality* within the Zutphen Study, according to updated covariates at each measurement round
Smoking state
Overall smoking Cigarette smoking
Crude HR (95% CI) Adjusted HR (95% CI) Crude HR (95% CI) Adjusted HR (95% CI)
All cause Recent ex-smoker` 1.57 (1.31 to 1.89) 1.47 (1.21 to 1.77) 1.51 (1.28 to 1.78) 1.39 (1.17 to 1.65)
Current smoker 1.78 (1.53 to 2.08) 1.69 (1.44 to 1.99) 1.70 (1.48 to 1.96) 1.60 (1.38 to 1.86)
Total cardiovascular Recent ex-smoker 1.40 (1.09 to 1.80) 1.51 (1.15 to 1.99)1 1.41 (1.12 to 1.76) 1.38 (1.09 to 1.74)
Current smoker 1.55 (1.26 to 1.91) 1.78 (1.41 to 2.24)1 1.56 (1.29 to 1.89) 1.66 (1.35 to 2.03)
Coronary heart disease Recent ex-smoker 1.37 (0.96 to 1.95) 1.27 (0.89 to 1.83) 1.42 (1.04 to 1.95) 1.33 (0.96 to 1.85)
Current smoker 1.35 (1.01 to 1.82) 1.54 (1.13 to 2.10) 1.41 (1.07 to 1.86) 1.59 (1.18 to 2.13)
Total cancer Recent ex-smoker 1.74 (1.24 to 2.44) 1.28 (0.91 to 1.82) 1.54 (1.15 to 2.08) 1.15 (0.84 to 1.57)
Current smoker 1.93 (1.45 to 2.57) 1.51 (1.11 to 2.05) 1.81 (1.40 to 2.33) 1.40 (1.07 to 1.83)
Lung cancer Recent ex-smoker 2.80 (1.44 to 5.44) 2.00 (1.02 to 3.92) 2.29 (1.35 to 3.88) 1.72 (1.00 to 2.95)
Current smoker 3.86 (2.17 to 6.87) 2.93 (1.60 to 5.35) 3.25 (2.08 to 5.08) 2.34 (1.47 to 3.75)
COPD Recent ex-smoker 2.15 (1.21 to 3.85) 2.29 (1.27 to 4.13) 2.96 (1.78 to 4.92) 2.98 (1.78 to 5.01)
Current smoker 2.43 (1.48 to 4.00) 2.23 (1.32 to 3.76) 3.30 (2.09 to 5.21) 2.90 (1.80 to 4.68)
COPD, chronic obstructive pulmonary disease.
*Because of missing data, the number of events may be smaller than the number mentioned in table 1.
Hazard ratio adjusted for energy intake, alcohol use, body mass index, baseline socioeconomic status, prevalence of myocardial infarction, stroke, diabetes mellitus
and cancer; cigarette smoking is additionally adjusted for cigar or pipe smoking.
`Recent ex-smokers are defined as men who stopped smoking ,10 years ago.
1Hazard ratios were calculated using mean survival age (76 years).
Table 3 Modelling cigarette smoking history in relation to mortality* within the Zutphen Study,
according to updated covariates at each measurement round
Crude HR (95% CI) Adjusted HR (95% CI)` Adjusted HR (95% CI)1
All cause
No of cigarettes smoked
(per 10 cigarettes/day)
1.22 (1.13 to 1.32) 1.10 (1.00 to 1.20) 1.11 (1.01 to 1.21)
Duration (per 10 years) 1.11 (1.08 to 1.14) 1.13 (1.07 to 1.18) 1.12 (1.06 to 1.18)
Total cardiovascular
No of cigarettes smoked
(per 10 cigarettes/day)
1.11 (1.00 to 1.24) 0.99 (0.88 to 1.13) 1.06 (0.93 to 1.20)
Duration (per 10 years) 1.09 (1.04 to 1.13) 1.13 (1.06 to 1.21) 1.15 (1.07 to 1.23)
Coronary heart disease
No of cigarettes smoked
(per 10 cigarettes/day)
1.12 (0.97 to 1.30) 1.05 (0.88 to 1.25) 1.17 (0.98 to 1.39)
Duration (per 10 years) 1.07 (1.01 to 1.14) 1.08 (0.98 to 1.20) 1.10 (1.00 to 1.21)
Total cancer
No of cigarettes smoked
(per 10 cigarettes/day)
1.36 (1.20 to 1.54) 1.25 (1.08 to 1.45) 1.14 (0.97 to 1.32)
Duration (per 10 years) 1.17 (1.10 to 1.24) 1.12 (1.02 to 1.22) 1.07 (0.96 to 1.19)
Lung cancer
No of cigarettes smoked
(per 10 cigarettes/day)
1.65 (1.38 to 1.98) 1.36 (1.10 to 1.70) 1.14 (0.90 to 1.44)
Duration (per 10 years) 1.42 (1.26 to 1.61) 1.29 (1.09 to 1.52) 1.31 (1.07 to 1.60)
COPD
No of cigarettes smoked
(per 10 cigarettes/day)
1.18 (0.95 to 1.48) 0.81 (0.62 to 1.07) 0.99 (0.73 to 1.33)
Duration (per 10 years) 1.34 (1.20 to 1.49) 1.51 (1.28 to 1.78) 1.38 (1.17 to 1.63)
COPD, chronic obstructive pulmonary disease.
*Because of missing data, the number of events may be smaller than the number mentioned in table 1.
Crude HR, hazard ratio for separate models for duration and the number of cigarettes (adjusted for ever smoking (yes/
no)).
`HR for multivariate models including duration of cigarette smoking and the number of cigarettes smoked, adjusted for
ever smoking.
1HR for multivariate models with additional adjustment for cigar or pipe smoking, energy intake, alcohol use, body mass
index, baseline socioeconomic status and the prevalence of myocardial infarction, stroke, diabetes mellitus and cancer.
HRs were calculated using mean survival age (76 years).
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DM and cancer—by 5.8 years. For current overall smoking, the
adjusted difference in life expectancy between smokers and
never or long-term ex-smokers was comparable to cigarette
smoking (table 4). Among the exclusive cigar or pipe smokers,
life expectancy was reduced by 4.7 (1.5 to 8.0) years and the
number of disease-free years of life by 3.7 (–1.7 to 9.1) years.
After adjustment for potential confounders, the total number of
life-years lost due to cigar or pipe smoking was 4.7 (1.4 to
8.0) years and the number of disease-free life-years lost was 5.2
(–1.5 to 12.0) years.
In addition, the number of total and disease-free years of life
lost increased when more cigarettes were smoked (table 4). The
adjusted number of total life-years lost ranged from 2.1 years
for men who smoked 11–20 cigarettes per day to 8.8 years for
men who smoked .30 cigarettes per day, whereas the number
of disease-free life-years lost ranged from 2.1 years to about
10.6 years. Men who stopped smoking at age 40 gained 4.6 life-
years, compared with men who continued smoking at that age
(table 4), while the gained life-years were 2.5–3.3 years among
men who stopped smoking at age 50, 60 or 70 years. The
number of disease-free years of life gained by stopping smoking
after age 40 were less compared with the total number of life-
years gained, but still 0.3–3.0 years.
DISCUSSION
Our results clearly show the importance of amount, duration
and type of smoking in relation to mortality. Average cigarette
smoking reduced life expectancy at age 40 by about 7 years,
and heavy cigarette smoking reduced life expectancy even
more. The average cigar or pipe smoker lost about 5 life-years.
Smoking decreased total life expectancy, and also decreased the
number of disease-free years of life, but to a smaller extent.
Moreover, stopping cigarette smoking at age 40 increased the
total life expectancy by about 5 years and the number of
disease-free years of life by about 3 years.
The major strength of this study was the collection of detailed
information on smoking habits at each of seven examination
rounds during 40 years of follow-up. This enabled us to study
the long-term effects of cigarette as well as cigar or pipe
smoking on mortality and life expectancy. Moreover, detailed
data on potential confounders made it possible to study the
independent effect of smoking. Adjustment for potential
confounders reduced the number of life-years lost by half a
year.
This study also has weaknesses. Firstly, the Zutphen Study
had a relatively small study population, which may have led to
less precise results. Secondly, the number of never smokers was
also very small, and we were therefore forced to combine men
who stopped smoking for >10 years with men who never
smoked in our reference group. Because studies suggested that
mortality risk after 10 years of smoking cessation is comparable
to that in never smokers,2 20 we used this cut-off value.
However, more recent studies showed that mortality risk is
comparable to that in never smokers only after 10–1521–24 or
more24–26 years of cessation, and so the differences in life
expectancy might have been underestimated. Thirdly, the
Zutphen Study started in 1960 with 872 men. The cohort of
Figure 2 Survival curves for cigarette smokers and never and long-term
ex-smokers within the Zutphen Study, adjusted for baseline energy intake,
alcohol use, body mass index, prevalence of myocardial infarction, stroke,
diabetes mellitus and cancer, socioeconomic status, and cigar or pipe
smoking.
Table 4 Differences in life expectancy (in years) due to smoking within the Zutphen Study,
crude and adjusted for potential confounders
Total life expectancy Disease-free years of life
Crude difference
(95% CI)
Adjusted difference
(95% CI)*
Crude difference
(95% CI)
Adjusted difference
(95% CI)*
Current overall
smoking
–6.8 (–9.1 to –4.5) –6.5 (–11.5 to –1.4) –5.8 (–8.5 to –3.1) –5.9 (–8.6 to –3.1)
Current cigarette
smoking
–7.5 (–10.1 to –4.9) –6.8 (–9.3 to –4.3) –5.9 (–8.8 to –3.0) –5.8 (–8.6 to –2.9)
No of cigarettes
smoked
1–10 –4.3 (–7.0 to –1.6) –4.3 (–7.1 to –1.4) –2.8 (–5.6 to 0.1) –2.9 (–5.9 to 0.0)
11–20 –2.3 (–4.0 to –0.5) –2.1 (–4.1 to –0.2) –2.1 (–4.7 to 0.5) –2.1 (–4.6 to 0.3)
21–30 –5.7 (–8.5 to –2.8) –5.8 (–8.6 to –2.9) –8.1 (–11.3 to –4.9) –8.2 (–11.3 to –5.0)
.30 –8.9 (–14.0 to –3.8) –8.8 (–13.9 to –3.7) –11.0 (–16.2 to –5.7) –10.6 (–14.9 to –6.3)
Stopped at age`
(years)
40 5.5 (3.3 to 7.6) 4.6 (2.3 to 6.8) 3.6 (0.9 to 6.4) 3.0 (0.4 to 5.6)
50 3.8 (2.3 to 5.4) 3.3 (1.9 to 4.7) 2.6 (0.7 to 4.5) 1.7 (–0.2 to 3.5)
60 3.3 (2.2 to 4.4) 2.8 (1.7 to 4.0) 1.2 (–0.2 to 2.7) 0.7 (–0.9 to 2.3)
70 2.6 (1.8 to 3.4) 2.5 (1.6 to 3.4) 0.5 (–1.1 to 2.0) 0.3 (–1.3 to 1.9)
*Difference adjusted for baseline energy intake, alcohol use, body mass index, prevalence of myocardial infarction,
stroke, diabetes mellitus and cancer, and socioeconomic status. Current cigarette smoking was additionally adjusted for
cigar or pipe smoking.
The number of life-years lost compared with never or long-term ex-smokers—that is, men who stopped smoking
>10 years ago.
`The differences represent the number of life-years lost compared with continuing smoking at that age.
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men who survived until 1985 was expanded with an additional
cohort of 559 men. However, as this additional cohort of men
was from the same birth cohort as the men who started the
study in 1960, it is unlikely that bias was introduced.
Our findings confirmed results from others that also showed
an increase in all-cause mortality risk with cigarette smoking
duration and the number of cigarettes smoked.9 13–15 20 23 27–30
After the adjustment for the prevalence of MI, stroke, DM and
cancer, only cigarette smoking duration was found to be
associated with lung cancer mortality. By omitting this
adjustment for chronic disease prevalence, both smoking
duration as well as the number of cigarettes smoked were
found to be strongly associated with total cancer and lung
cancer mortality. This result confirms those from other
studies.9–11 15 20 28–30 In addition, we confirmed the results of
other studies which showed dose–response relationships
between smoking duration and COPD mortality.9 15
In accordance with other studies,6 7 the effects of cigar or pipe
smoking on mortality were weaker compared with the effects of
cigarette smoking. To our knowledge, we are the first to report
on the effects of exclusive cigar or pipe smoking on life
expectancy. This study found that the effects on life expectancy
observed for cigar or pipe smoking were close to those observed
for cigarette smoking. Exclusive cigar or pipe smoking reduced
life expectancy by about 5 years, whereas cigarette smoking
reduced life expectancy by about 7 years.
In the British Doctors Study,4 the Framingham Heart Study31
and the Cancer Prevention Study II,32 the reduction in life
expectancy due to smoking was about 9 years. The difference in
the reduction in life expectancy compared with this study may
be due to several factors. Firstly, life expectancy within these
studies was assessed at different ages. Secondly, men who
stopped smoking >10 years ago were not included in the
reference group. Thirdly, the adjustment for possible confoun-
ders was not carried out in these studies and, finally, the
average amount smoked might have been higher compared
with that in this study. Both the British Doctors Study29 as well
as our study found that heavy cigarette smokers lost 9–10 life-
years, indicating that the amount smoked is associated with
reductions in life expectancy.
In accordance with the British Doctors Study4 and the Cancer
Prevention Study II,32 we found that smoking cessation has
beneficial effects on life expectancy. These studies as well as
this study found a substantial increase in life expectancy of
about 3 years when stopping smoking at age 60. The main
focus in smoking prevention programmes is preventing smok-
ing initiation. The results from this and other studies indicate
that the persuasion of smokers to quit smoking, even later in
life, should be another important focus from a public health
perspective.
In this study, the reduction in the number of disease-free
years of life due to smoking was comparable between the
different types of smoking. Other studies also addressed the
differences in the number of disease-free years of life.31 33 34
Although these studies defined disease-free years of life
differently from this study and did not distinguish between
different types of smoking, the overall conclusions were similar.
Never smokers and quitters live longer than continuing
smokers, and they also spend more years of life in better health.
In summary, cigarette and cigar or pipe smoking reduces life
expectancy and the number of disease-free years of life.
However, the number of life-years lost due to cigar or pipe
smoking is fewer compared with cigarette smoking. Both the
number of cigarettes smoked and smoking duration are
strongly associated with mortality risk and the number of
life-years lost. Although our results indicate that the effects will
be larger the earlier one quits, even stopping at age 60 has
major benefits on life expectancy.
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T
he following electronic only article is published in
conjunction with this issue of Tobacco Control.
Asian herbal-tobacco cigarettes: ‘‘not medicine but less
harmful’’?
Aiyin Chen, Stanton Glantz, Elisa Tong
Objective: To describe the development and health claims of
Asian herbal-tobacco cigarettes.
Methods: Analysis of international news sources, company
websites, and the transnational tobacco companies’ (TTC)
documents. PubMed searches of herbs and brands.
Results: Twenty-three brands were identified, mainly from
China. Many products claimed to relieve respiratory symptoms
and reduce toxins, with four herb-only products advertised for
smoking cessation. No literature was found to verify the health
claims, except one Korean trial of an herb-only product. Asian
herbal-tobacco cigarettes were initially produced by China by
the 1970s and introduced to Japan in the 1980s. Despite initial
news about research demonstrating a safer cigarette, the TTC
analyses of these cigarettes suggest that these early products
were not palatable and had potentially toxic cardiovascular
effects. By the late 1990s, China began producing more herbal-
tobacco cigarettes in a renewed effort to reduce harmful
constituents in cigarettes. After 2000, tobacco companies from
Korea, Taiwan, and Thailand began producing similar products.
Tobacco control groups in Japan, Taiwan, and Thailand voiced
concern over the health claims of herbal-tobacco products. In
2005, China designated two herbal-tobacco brands as key for
development.
Conclusion: Asian herbal-tobacco cigarettes claim to reduce
harm, but no published literature is available to verify these
claims or investigate unidentified toxicities. The increase in
Asian herbal-tobacco cigarette production by 2000 coincides
with the Asian tobacco companies’ regular scientific meetings
with TTCs and their interest in harm reduction. Asia faces
additional challenges in tobacco control with these culturally
concordant products that may discourage smokers from
quitting.
(Tobacco Control 2007;16:e3) www.tobaccocontrol.com/cgi/
content/full/16/2/e3
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